Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPYD-NOW study in non-Western patients receiving fluoropyrimidines
NL-OMON49023Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fluorouracil and capecitabine in breast cancer, colorectal cancer (CRC) and gastric cancer (GC), sponsored by Leiden University Medical Center. Started Nov 2020; status: active, not recruiting.
02
Drugs
fluorouracilcapecitabine
03
Conditions
breast cancercolorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON49023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49023.